Duke Cancer

Duke Rides is coming! Recruit four or more riders, fundraise together, & earn your spot on the bikes for an indoor cycling relay. Every dollar raised fuels lifesaving cancer research and care. Register your team & start fundraising today: duke.is/DukeRides @DukeMedSchool

A pioneering blood test detected more than twice as many high-risk prostate cancer cases as current methods. DCI's Kevin Oeffinger, MD, spoke with @Telegraph about the test's potential. duke.is/6/7tb6 @DukeHealth | #ProstateCancer

DCI's Jung Wook Park, PhD, recently presented research on treatment resistance in prostate cancer at the Molecular Medicine Seminar hosted by @UTHealthSA. duke.is/z/ph5e #ProstateCancer | #CancerResearch | @DukeHealth

The FDA approved a new combination of drugs as the first and only targeted treatment for adult patients with a particular, aggressive subtype of prostate cancer. DCI's Daniel George, MD, was an investigator on the trial. duke.is/2/3vdc @DukeGUCancer | @DukeHealth

Research from DCI's Gerald Grant, MD, focuses on using low-frequency ultrasound to open the blood brain barrier of patients with brain cancer. duke.is/9/4vn5 #BrainCancer | #CancerResearch | Duke University School of Medicine

Colon cancer rates have risen sharply in the last decade, especially for younger people. DCI's Nicholas DeVito, MD, spoke with @newsobserver about how to mitigate the risk of colon cancer. duke.is/b/wva7 #ColonCancer | #CancerResearch | @DukeHealth

Breast density influences a woman’s cancer risk and the effectiveness of mammography. At Duke Health, breast imaging specialists personalize each patient’s screening plan with evidence-based risk assessment protocols. duke.is/5/8h7t #BreastCancer | @DukeHealth

A new program is giving pancreatic cancer patients the opportunity to receive a new drug that may improve overall survival time in critically ill patients. DCI is among the institutes involved in this program. duke.is/j/wcsu #PancreaticCancer | @DukeHealth

Cellular therapies are showing tremendous promise for certain cancers previously thought to be incurable. DCI's Diane Reidy-Lagunes, MD, and Chenyu Lin, MD, discuss how they work and what the future may hold. duke.is/g/2wps @DukeHealth | @DukeMedSchool

A team from @DukePathDept has been awarded a five-year Program Project Grant from @theNCI to investigate new treatment approaches for neuroendocrine #ProstateCancer. duke.is/9/767h @DukeMedSchool

Something new is coming to Duke. Join us on Oct. 3 for Duke Rides, the inaugural indoor cycling fundraiser benefiting DCI. 📆 Saturday, Oct. 3 ⏰ 12-5 p.m. 📍 Wilson Recreation Center, Durham, NC Learn more and register: duke.is/DukeRides @DukeMedSchool

DCI's Ming Chen, PhD, Yarui Diao, PhD, and Anoop Patel, MD, have received a federal grant to develop a technology that has the potential to reshape how researchers understand cancer at its earliest, most aggressive stages. duke.is/p/n869 @DukePathDept | @DukeMedSchool

DCI's Everardo Macias, PhD, and Andrew Armstrong, MD, have been awarded a V Foundation Translational Research Grant to develop new treatment strategies for aggressive, treatment‑resistant #ProstateCancer. duke.is/n/fanr @DukePathDept | @DukeMedSchool

At the annual #ASCO26 meeting, DCI’s Michael J. Kelley, MD, and Harvey Jay Cohen, MD, received national honors reflecting careers dedicated to expanding veterans’ access to care and shaping care of older adults. @DukeMedSchool

Research from DCI is helping uncover why some bladder cancer patients are less likely to benefit from a common treatment and how cancer history may help guide personalized care decisions. duke.is/2/kwjy #BladderCancer | #CancerResearch | @DukeHealth | @DukeMedSchool

Congratulations to DCI's Sanghee Hong, MD, on receiving a career development award from @ASCO Conquer Cancer Foundation to advance research aimed at improving access to potentially curative cancer treatments. duke.is/8/grh5 #ASCO26 | #CancerResearch | @DukeRadOnc

Bladder cancer care is complex, time-sensitive, and often nuanced. DCI launched a dedicated multidisciplinary bladder cancer clinic designed to deliver coordinated, expert care across the entire disease continuum. duke.is/j/hyhe #BladderCancer | @DukeHealth

A study led by DCI's Lee Zou, PhD, suggests a new way to predict which patients are most likely to benefit from a promising class of experimental cancer drugs called ATR inhibitors. duke.is/z/5c4m #CancerBiology | #CancerResearch | @DukeMedSchool | @Duke_PCB

So proud of Dr. Sanghee Hong @hongsmd, recipient of a prestigious Career Development Award from @ASCO @ConquerCancerFd, conferred today at the world's largest gathering devoted to advancing cancer care. Sanghee, you make us proud @DukeCancer @dukemedicine @DukeHMCT! Congratulations! #ASCO26

The #ADREAM trial from #ASCO26 offers insight into time off therapy for patients with metastatic prostate cancer and great response to ADT/ARPI. Important data from @ALLIANCE_org. @hannahdzmd @DCockrellMD @DukeGUCancer @AarmstrongDuke @DukeCancer